Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech has announced promising developments, including the advancement of their drug pelareorep to a pivotal study in pancreatic cancer and impressive response rates in anal carcinoma, signaling potential enrollment expansion. The company expects to release overall survival data from a breast cancer study in 2024 and maintains a solid cash position of $34.9 million, ensuring funding through key milestones into 2025. These developments highlight Oncolytics’ transition to a late-stage oncology company with a focus on immunotherapeutic treatments.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
